SNDX - Syndax Pharmaceuticals Inc. (SNDX) Q1 2024 Earnings Call Transcript
2024-05-08 16:08:09 ET
Syndax Pharmaceuticals, Inc. (SNDX)
Q1 2024 Earnings Conference Call
May 08, 2024, 08:00 ET
Company Participants
Sharon Klahre - Head, Investor Relations
Michael Metzger - CEO & Director
Steve Closter - Chief Commercial Officer
Keith Goldan - CFO
Neil Gallagher - President, Head of Research and Development
Anjali Ganguli - Chief Business Officer
Conference Call Participants
Peter Lawson - Barclays Capital
Anupam Rama - JPMorgan Securities
Brad Canino - Stifel, Nicolaus & Company
Phil Nadeau - Cowen & Co.
Michael Schmidt - Guggenheim Securities
Yigal Nochomovitz - Citigroup
Kalpit Patel - B. Riley Securities
Jason Zemansky - Bank of America Merrill Lynch
Justin Zelin - BTIG
Chris Shibutani - Goldman Sachs & Co.
George Farmer - Scotia Capital
Presentation
Operator
Good day, everyone, and welcome to the Syndax First Quarter 2024 Earnings Conference Call. Today's call is being recorded.
At this time, I'd like to turn the call over to Sharon Klahre, Head of Investor Relations at Syndax Pharmaceuticals.
Sharon Klahre
Thank you, operator. Welcome, and thank you all for joining us today for a review of Syndax's first-quarter 2024 financial and operating results. I'm Sharon Klahre. And with me this afternoon to provide an update on the company's progress and discuss financial results are Michael Metzger, Chief Executive Officer; Dr. Neil Gallagher, President and Head of R&D; Steve Closter, Chief Commercial Officer; Keith Goldan, Chief Financial Officer. Also joining us on the call today for the question-and-answer session are Dr. Peter Ordentlich Chief Scientific Officer; and Dr. Anjali Ganguli, Chief Business Officer.
This call is accompanied by a slide deck that is posted on the Investor page of the company's website. You can now turn to our forward-looking statements on slide 2.
Before we begin, I'd like to remind you that any statements made during the call that are not historical are considered to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these statements as a result of various important factors, including those discussed in the risk factors section in the company's most recent quarterly reports on Form 10-Q as well as other reports filed with the SEC.
Any forward-looking statements made represent our views as of today, May 8, 2024, only. A replay of this call will be available on the company's website, www.syndax.com following its completion.
With that, I am pleased to turn the call over to Michael Metzger, Chief Executive Officer of Syndax....
Syndax Pharmaceuticals, Inc. (SNDX) Q1 2024 Earnings Call Transcript